1 The analysts offering a 1-year price forecast for NBY stock have a bullish outlook for the upcoming weeks. 2 As per the analysts, the NovaBay stock price may reach a high of $9.50 in a year. 3 The daily chart shows that the price has been experiencing a free fall for the last f...
- 1 The analysts offering a 1-year price forecast for NBY stock have a bullish outlook for the upcoming weeks.
- 2 As per the analysts, the NovaBay stock price may reach a high of $9.50 in a year.
- 3 The daily chart shows that the price has been experiencing a free fall for the last few weeks wiping out over 90% of the market cap.
NovaBay Pharmaceuticals Inc. stock price shows an accumulation near the all-time low. The bulls are attempting to halt the further decline. Moreover, the sellers are dominating the price trend and dragging the price down each time the bulls try to get into the game.
The bulls are losing continuously and the price is experiencing a free fall for several weeks. The NBY stock price is down over 84.29% on a year-to-date basis and down by over 95% in the past two years.
However, NovaBay Inc. is yet to announce quarterly earnings on Thursday, 9th November, post which, the price trend may turn around. The analysts are hoping for an optimistic trend after the results.
The bulls are losing continuously and the price is experiencing a free fall for several weeks. The NBY stock price is down over 84.29% on a year-to-date basis and down by over 95% in the past two years.
However, NovaBay Inc. is yet to announce quarterly earnings on Thursday, 9th November, post which, the price trend may turn around. The analysts are hoping for an optimistic trend after the results.
Analysts Hoping For Optimistic Trend After Quarterly Results
NovaBay Pharmaceuticals engages in the research, development, and sales of scientifically created and clinically proven eye care and skin care. Founded in 2000, the company holds a market cap of $1.39 Million.
NovaBay is yet to announce quarterly results today which might play a crucial role in deciding the next directional move of the stock price. The Wall Street analysts are expecting the company to deliver a revenue of $3.547 Million.
The analysts are also expecting earnings of negative $0.045 per share. The company is required to deliver outperforming earnings to gain back the trust of investors. It will further improve the share price.
NovaBay Pharmaceuticals Stock Price Prediction 2023
Source: NovaBay Pharmaceuticals NYSE By TradingView
The NBY stock price prediction for 2023 signifies a mixed outlook in the current quarter. The most optimistic view of analysts expects the price to reach a high of $120 by the end of 2023. However, the pessimistic view of analysts expects a price decline to $0.206.
NovaBay Pharmaceuticals Stock Price Prediction 2024
Analysts offering yearly price forecasts for NovaBay stock have a bullish outlook about the company. As per the analysts, the pharmaceuticals industry may grow more in the upcoming years and so will the company. The most optimistic outlook of the analysts expects the price to reach a high of $9.60 indicating an upside potential of 2700%.
On the flip side, the minimum estimates of analysts expect the stock price to reach a high of $3.6 by the end of 2024.
Conclusion
NovaBay Pharmaceuticals stock price has been in a sharp decline for several weeks delivering a bearish outlook. The stock price fell below the key EMAs of 50-day and 200-day. The company is yet to announce quarterly results which may impact the price trend.
A good quarterly result may regain the trust of investors and the stock price may improve. The analysts have a bullish outlook for 2024 and expect the price to reach a high of $9.60 if the most optimistic conditions are met.
Technical Levels
- Support Levels: $0.311 and $0.20
- Resistance Levels: $0.799 and $1.20
Disclaimer
The views and opinions stated by the author, or any people named in this article, are for informational purposes only and do not establish financial, investment, or other advice. Investing in or trading crypto or stock comes with a risk of financial loss.